Your browser doesn't support javascript.
loading
Use of a population pharmacokinetic approach for the clinical development of a fixed-dose subcutaneous formulation of trastuzumab.
Hourcade-Potelleret, F; Lemenuel-Diot, A; McIntyre, C; Brewster, M; Lum, B; Bittner, B.
Affiliation
  • Hourcade-Potelleret F; 1] Clinical Modeling & Simulation, F. Hoffmann-La Roche Ltd., Basel, Switzerland [2] Current address: Novartis Pharma AG, Postfach, Basel, Switzerland.
  • Lemenuel-Diot A; Clinical Modeling & Simulation, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • McIntyre C; Clinical Pharmacology, Roche Products Ltd, Welwyn Garden City, UK.
  • Brewster M; Clinical Pharmacology, Roche Products Ltd, Welwyn Garden City, UK.
  • Lum B; Genentech Inc., South San Francisco, California, USA.
  • Bittner B; 1] Clinical Pharmacology, Roche Products Ltd, Welwyn Garden City, UK [2] Product Optimization, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
CPT Pharmacometrics Syst Pharmacol ; 3: e87, 2014 Jan 02.
Article in En | MEDLINE | ID: mdl-25019376
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2014 Document type: Article Affiliation country: Suiza Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2014 Document type: Article Affiliation country: Suiza Country of publication: Estados Unidos